GT Biopharma, Inc. (GTBP) - Dilution Analysis

10-Q filing | 36.1M shares outstanding

10-Q filing | 10.6M shares outstanding

S-1 filing: This prospectus relates to the offering from time to time by the selling stockholders named in this prospectus of up to an aggregate 14,589,546 shares of common stock of GT Biopharma, Inc.

10-Q filing | 3.6M shares outstanding

S-1/A filing: This prospectus relates to the offering from time to time by the selling stockholders of up to an aggregate 54,423,826 shares of common stock.

S-1 filing: This S-1 filing registers 120,553,632 shares of common stock for offering by selling stockholders, including shares issuable upon conversion of preferred stock and exercise of warrants, and shares that may be sold to Facility Investors.

8-K filing: GT Biopharma, Inc. amended its Securities Purchase Agreement to increase the number of shares of Series L 10% Convertible Preferred Stock issuable to 6,612 shares, with accompanying warrants, for an aggregate purchase price of $5,950,000.00 and also filed a Certificate of Increase increasing the shares of Series L 10% Convertible Preferred Stock from 28,056 shares to 30,630 shares. ($5.95M proceeds)

10-Q filing | 2.3M shares outstanding

8-K filing: GT Biopharma, Inc. entered into a Securities Purchase Agreement for the issuance and sale of Series L 10% Convertible Preferred Stock, warrants to purchase common stock, and vesting warrants, with an aggregate stated value of $6,055,555.56, for an aggregate purchase price of $5,450,000.00. ($5.45M proceeds)

8-K filing: GT Biopharma, Inc. issued a pre-funded warrant to Cytovance Biologics, Inc. to purchase up to 326,251 shares of Common Stock in partial consideration for services provided. ($0.85M proceeds)

S-3 filing: This prospectus relates to the resale of up to 625,283 shares of common stock issuable upon the exercise of warrants.

8-K filing: GT Biopharma, Inc. entered into warrant exercise inducement offer letter agreements with certain holders of existing warrants to purchase 302,069 shares of common stock at a reduced exercise price of $2.27 per share, in exchange for the issuance of new Series A and Series B Inducement Warrants to purchase up to 604,138 shares of common stock at an exercise price of $2.02 per share, resulting in gross proceeds of approximately $0.7 million. ($0.0M proceeds)

RW filing: GT Biopharma, Inc. is withdrawing its Registration Statement on Form S-1 initially filed on December 23, 2024, because it no longer plans to consummate the offering described in the Registration Statement.

10-K filing | 2.2M shares outstanding

S-1/A filing: This S-1/A filing is for a best efforts public offering of shares of common stock, common warrants, and pre-funded warrants.

S-1/A filing: This is a reasonable best efforts public offering of shares of common stock, common warrants to purchase shares of common stock, and pre-funded warrants.

S-1 filing: This S-1 filing describes a best efforts public offering of common stock, pre-funded warrants, common warrants, and placement agent warrants, with Roth Capital Partners, LLC acting as the exclusive placement agent.

10-Q filing | 2.2M shares outstanding

10-Q filing | 2.2M shares outstanding

S-1/A filing: This S-1/A filing registers the offer and resale of up to 740,000 shares of common stock issuable upon the exercise of warrants with an exercise price of $4.35, issued in a concurrent private placement on May 21, 2024. The company will not receive any proceeds from the sale of these shares.

S-1 filing: This S-1 filing registers the offer and resale of up to 740,000 shares of common stock by selling shareholders, issuable upon the exercise of warrants issued in a concurrent private placement.

8-K filing: GT Biopharma, Inc. entered into a purchase agreement with institutional investors to issue and sell 740,000 shares of common stock in a registered direct offering at $4.35 per share and agreed to issue warrants to purchase one share of common stock for each share purchased in the offering. ($3.22M proceeds)

10-Q filing | 1.4M shares outstanding

10-K filing | 1.3M shares outstanding

10-Q filing | 41.0M shares outstanding

10-Q filing | 40.2M shares outstanding

10-Q filing | 39.1M shares outstanding

10-K filing | 36.8M shares outstanding

8-K filing: GT Biopharma, Inc. completed a registered direct offering of 3,600,000 shares of common stock, pre-funded warrants to purchase up to 2,900,000 shares, and warrants to purchase up to 6,500,000 shares at a combined price of $1.00 per share/warrant or $0.9999 per pre-funded warrant/warrant, resulting in gross proceeds of $6.5 million. ($6.5M proceeds)

10-Q filing | 31.4M shares outstanding

S-3 filing: GT Biopharma files an S-3 registration statement to offer up to $150,000,000 in common stock and/or warrants or rights to purchase such securities.

8-K filing: The Registrant entered into a Settlement and Investment Agreement with Cytovance Biologics, Inc. to modify payment terms, issuing 1,222,281 shares of common stock to satisfy $3,251,267.75 of outstanding invoices and agreeing to future payments in cash and common stock, while limiting Cytovance's ownership to 4.9% of the Registrant's common stock. ($3.25M proceeds)

10-Q filing | 31.2M shares outstanding

10-Q filing | 32.5M shares outstanding

10-K filing | 32.1M shares outstanding

10-Q filing | 30.5M shares outstanding

10-Q filing | 5.2M shares outstanding

10-Q filing | 21.1M shares outstanding

S-1 filing: This is an S-1 filing for a potential offering of common stock by selling shareholders, with no guaranteed sale of shares and subject to market regulations.

POS AM filing: This prospectus relates to the issuance by GT Biopharma, Inc. of (i) 4,368,280 shares of common stock upon the exercise of 4,368,280 warrants and (ii) 247,250 shares of Common Stock that may be issued upon the exercise of 247,250 warrants.

10-K filing | 28.4M shares outstanding

S-1/A filing: This is an S-1/A filing for GT Biopharma, Inc., a clinical stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products, including information on convertible notes, warrants and preferred stock.

S-1/A filing: This S-1/A filing discusses the automatic conversion of Bridge Notes and cancellation of Settlement Warrants into common stock and warrants, leading to potential dilution for investors.

S-1 filing: The company is filing an S-1 form and plans to convert Bridge Notes into common stock and warrants, and issue shares upon cancellation of Settlement Warrants.

10-Q filing | 69.8M shares outstanding

10-Q filing | 69.8M shares outstanding

S-1 filing: This is an S-1 filing for GT Biopharma, Inc. The filing discusses financial results, business plans, and the offering of various securities including convertible notes, preferred stock, warrants and common stock. The company focuses on developing immuno-oncology products.

10-Q filing | 70.1M shares outstanding

10-K filing | 50.7M shares outstanding